S
SYRE icon

SignatureFD’s Spyre Therapeutics SYRE Stock Holding History

SignatureFD’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.24K Sell
59
-11
-16% -$803 ﹤0.01% 2852
2026
Q1 		$3.53K Hold
70
– – ﹤0.01% 2895
2025
Q4 		$2.29K Hold
70
– – ﹤0.01% 2931
2025
Q3 		$1.17K Sell
70
-95
-58% -$1.55K ﹤0.01% 3055
2025
Q2 		$2.47K Buy
+165
New +$2.44K ﹤0.01% 2816
2025
Q1 		– Sell
-68
Closed -$1.58K – 3440
2024
Q4 		$1.58K Buy
+68
New +$1.99K ﹤0.01% 2928

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SignatureFD's SYRE Position: Q2 2026 in Review

SignatureFD reduced its Spyre Therapeutics (SYRE) stake by 16% in Q2 2026, selling an estimated $803 and leaving 59 shares worth $5.24K. The position accounts for ﹤0.01% of the portfolio, ranked #2852.

SignatureFD first reported a position in SYRE in Q4 2024 and has held it in 6 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • SignatureFD held 59 shares of Spyre Therapeutics worth $5.24K as of Q2 2026.
  • SignatureFD sold 11 Spyre Therapeutics shares in Q2 2026, an estimated $803.
  • Spyre Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2852 holding.
  • SignatureFD first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.